BerGenBio
0,32 NOK -1,39 %Vær den første som følger denne virksomhed
BerGenBio is a Norwegian oncology company. The company conducts research and development of inhibitory drugs for the treatment of aggressive cancers. The company has developed a number of products whose composition intends to block the protein AXL, a protein positively related to the spread of cancer cells. The company was founded in 2007 and is headquartered in Bergen.
Omsætning
390 t
EBIT %
-78.369,23 %
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
Oslo Børs
BGBIO
Daglig lav / høj pris
0,3 / 0,335
NOK
Markedsværdi
28,37 mio. NOK
Aktieomsætning
814,66 t NOK
Volumen
2,6 mio.
Finanskalender
Delårsrapport
22.06.2023
Delårsrapport
23.08.2023
Delårsrapport
14.11.2023
Årsrapport
15.02.2024
Viser Alle indholdstyper